ArticleNature communications2026
MRICombo: a deep-learning-based framework for universal volumetric segmentation grading-staging and malignancy detection across heterogeneous MRI.
Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- FD-MSP: feature decoupling network with multi-scale prototypes for domain-adaptive polyp segmentation.BMC medical imaging · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Comprehensive magnetic resonance imaging (MRI) analysis in oncology involves multiple interrelated tasks including volumetric segmentation, grading, staging, and malignancy detection. However, most existing deep learning models are task-specific or sequence-specific, lacking the generalizability required for heterogeneous sequences. Here we present MRICombo, a unified multi-expert deep learning framework for universal anatomical delineation and tumor characterization across 9 heterogeneous imaging sequences. Developed using 7,380 MRI sequences from 2,354 individuals, MRICombo achieves state-of-the-art performance with mean Dice similarity coefficients of 0.836 for segmenting 14 critical anatomical structures and 0.625 for labeling 11 major tumor types. It also attains a mean area under the receiver operating characteristic curve (AUROC) of 0.920 for glioma grading, bladder and nasopharyngeal cancer staging, and breast and liver tumor malignancy detection. External validation on four independent datasets (1082 sequences from 734 individuals) and transfer learning evaluation (512 individuals) confirm robust cross-protocol generalizability. Furthermore, MRICombo supports flexible inference with missing sequences and offers decision interpretability through sequence clustering and expert contribution analysis. As a unified clinical solution, MRICombo significantly reduces deployment costs and has the potential to streamline diagnostic workflows, supporting more personalized oncology care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.